Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial

The large majority of patients with HER2-positive metastatic breast cancer (MBC) will eventually develop resistance to anti-HER2 therapy and die of this disease. Despite, relatively high levels of stromal tumor infiltrating lymphocytes (sTILs), PD1-blockade has only shown modest responses. Monalizum...

Descripción completa

Detalles Bibliográficos
Autores principales: Geurts, V.C.M., Voorwerk, L., Balduzzi, S., Salgado, R., Van de Vijver, K., van Dongen, M.G.J., Kemper, I., Mandjes, I.A.M., Heuver, M., Sparreboom, W., Haanen, J.B.A.G., Sonke, G.S., Horlings, H.M., Kok, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336326/
https://www.ncbi.nlm.nih.gov/pubmed/37393645
http://dx.doi.org/10.1016/j.breast.2023.06.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336326/
https://www.ncbi.nlm.nih.gov/pubmed/37393645
http://dx.doi.org/10.1016/j.breast.2023.06.007

Ejemplares similares